FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to novel hydroquinone derivatives of formula (I), where Ra, Rb, R1-R3 are defined in the claim, intermediate compounds for producing hydroquinone derivatives of formula (I), as well as pharmaceutical compositions.
EFFECT: invention can be used for use in treatment and/or prevention, for example, autoimmune, immunologic, rheumatological, vascular, ophthalmic, fibrous, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, new growths and cancer-related diseases, hormonal diseases and immunological disorders resulting from viral and bacterial infectious diseases and their complications.
19 cl, 11 dwg, 59 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUND HAVING THROMBOCYTE AGGREGATION INHIBITION ACTION, AND A SALT THEREOF, AND A COMPOSITION COMPRISING SUCH COMPOUNDS FOR PREVENTING OR TREATING THROMBOTIC DISEASES | 2016 |
|
RU2739915C2 |
SUBSTITUTED N-ARYLBENZAMIDES AND RELATED COMPOUNDS FOR TREATING AMYLOID DISEASES AND SYNUCLEINOPATHY | 2005 |
|
RU2381213C2 |
METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
2-ARYLACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2004 |
|
RU2356887C2 |
HYDROXYBENZAMIDE DERIVATIVES AND USE THEREOF AS Hsp90 INHIBITORS | 2006 |
|
RU2458919C2 |
BENZOPYRANE AND BENZOCONDENSED COMPOUNDS, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND A METHOD OF INHIBITION | 1995 |
|
RU2128655C1 |
NEW COMPOUNDS FOR MODULATION OF CELLULAR PROLIFERATION | 2001 |
|
RU2277531C9 |
CRYSTALLINE ADDITION ACID SALTS OF CEPHEM, METHOD OF THEIR PRODUCING, DRUG CONTAINING THEREOF | 1995 |
|
RU2161619C2 |
PHOSPHONIUM SALTS BASED ON ALANTOLACTONE, HAVING ANTI-TUMOUR ACTIVITY, AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2818095C1 |
NOVEL 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN HUMAN TREATMENT AND IN COSMETICS | 2009 |
|
RU2499794C2 |
Authors
Dates
2024-10-01—Published
2021-03-08—Filed